{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T14:26:21Z","timestamp":1782743181018,"version":"3.54.5"},"reference-count":90,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T00:00:00Z","timestamp":1670544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>B cell lymphoma 2 (BCL-2) family proteins are involved in the mitochondrial apoptotic pathway and are key modulators of cellular lifespan, which is dysregulated during human immunodeficiency virus type 1 (HIV-1) and other viral infections, thereby increasing the lifespan of cells harboring virus, including the latent HIV-1 reservoir. Long-lived cells harboring integrated HIV-1 DNA is a major barrier to eradication. Strategies reducing the lifespan of reservoir cells could significantly impact the field of cure research, while also providing insight into immunomodulatory strategies that can crosstalk to other viral infections. Venetoclax is a first-in-class orally bioavailable BCL-2 homology 3 (BH3) mimetic that recently received Food and Drug Administration (FDA) approval for treatment in myeloid and lymphocytic leukemia. Venetoclax has been recently investigated in HIV-1 and demonstrated anti-HIV-1 effects including a reduction in reservoir size. Another immunomodulatory strategy towards reduction in the lifespan of the reservoir is Jak 1\/2 inhibition. The Jak STAT pathway has been implicated in BCL-2 and interleukin 10 (IL-10) expression, leading to a downstream effect of cellular senescence. Ruxolitinib and baricitinib are FDA-approved, orally bioavailable Jak 1\/2 inhibitors that have been shown to indirectly decay the HIV-1 latent reservoir, and down-regulate markers of HIV-1 persistence, immune dysregulation and reservoir lifespan <jats:italic>in vitro<\/jats:italic> and <jats:italic>ex vivo<\/jats:italic>. Ruxolitinib recently demonstrated a significant decrease in BCL-2 expression in a human study of virally suppressed people living with HIV (PWH), and baricitinib recently received emergency use approval for the indication of coronavirus disease 2019 (COVID-19), underscoring their safety and efficacy in the viral infection setting. BCL-2 and Jak 1\/2 inhibitors could be repurposed as immunomodulators for not only HIV-1 and COVID-19, but other viruses that upregulate BCL-2 anti-apoptotic proteins. This review examines potential routes for BCL-2 and Jak 1\/2 inhibitors as immunomodulators for treatment and cure of HIV-1 and other viral infections.<\/jats:p>","DOI":"10.3389\/fimmu.2022.1033672","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T10:31:25Z","timestamp":1670581885000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Repurposing BCL-2 and Jak 1\/2 inhibitors: Cure and treatment of HIV-1 and other viral infections"],"prefix":"10.3389","volume":"13","author":[{"given":"Monica D.","family":"Reece","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah C.","family":"Hancock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Pereira Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deanna A.","family":"Kulpa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Gavegnano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01009-17","article-title":"Picornaviruses and apoptosis: Subversion of cell death","volume":"8","author":"Croft","year":"2017","journal-title":"mBio"},{"key":"B2","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/cdd.2017.186","article-title":"BCL-2 family proteins: changing partners in the dance towards death","volume":"25","author":"Kale","year":"2018","journal-title":"Cell Death Differ"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006740","article-title":"Novel mechanisms to inhibit HIV reservoir seeding using jak inhibitors","volume":"13","author":"Gavegnano","year":"2017","journal-title":"PloS Pathog"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2009.03244.x","article-title":"Interleukin-7 promotes the survival of human CD4+ effector\/memory T cells by up-regulating bcl-2 proteins and activating the JAK\/STAT signalling pathway","volume":"130","author":"Chetoui","year":"2010","journal-title":"Immunology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2016.23","article-title":"The anti-apoptotic bcl-2 family protein A1\/Bfl-1 regulates neutrophil survival and homeostasis and is controlled via PI3K and JAK\/STAT signaling","volume":"7","author":"Vier","year":"2016","journal-title":"Cell Death Dis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/nri1226","article-title":"Regulation of JAK-STAT signalling in the immune system","volume":"3","author":"Shuai","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1093\/cid\/ciab212","article-title":"Randomized trial of ruxolitinib in antiretroviral-treated adults with human immunodeficiency virus","volume":"74","author":"Marconi","year":"2021","journal-title":"Clin Infect Dis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s12974-019-1565-6","article-title":"Baricitinib reverses HIV-associated neurocognitive disorders in a SCID mouse model and reservoir seeding in vitro","volume":"16","author":"Gavegnano","year":"2019","journal-title":"J Neuroinflamm"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02496-13","article-title":"Ruxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in vitro","volume":"58","author":"Gavegnano","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-08-042556","article-title":"Naturally occurring c-terminally truncated STAT5 is a negative regulator of HIV-1 expression","volume":"109","author":"Crotti","year":"2007","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11190","article-title":"Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL","volume":"7","author":"Yosef","year":"2016","journal-title":"Nat Commun"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0144","article-title":"Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy","volume":"15","author":"Kang","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2008.307","article-title":"Bcl-2 family proteins and cancer","volume":"27","author":"Yip","year":"2008","journal-title":"Oncogene"},{"key":"B14","volume-title":"HIV Surveillance report, 2020","year":"2022"},{"key":"B15","volume-title":"In danger: UNAIDS global AIDS update 2022","year":"2022"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2019.7108","article-title":"HIV Antiretroviral therapy costs in the united states, 2012-2018","volume":"180","author":"McCann","year":"2020","journal-title":"JAMA Intern Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0026-6","article-title":"Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in fiebig I acute HIV infection","volume":"24","author":"Colby","year":"2018","journal-title":"Nat Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00969-19","article-title":"Differentiation into an effector memory phenotype potentiates HIV-1 latency reversal in CD4(+) T cells","volume":"93","author":"Kulpa","year":"2019","journal-title":"J Virol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2019.109445","article-title":"Interleukin-10 induces senescence of activated hepatic stellate cells via STAT3-p53 pathway to attenuate liver fibrosis","volume":"66","author":"Huang","year":"2020","journal-title":"Cell Signal"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2017.01.028","article-title":"Anti-PD-1\/PD-L1 therapy for infectious diseases: learning from the cancer paradigm","volume":"56","author":"Rao","year":"2017","journal-title":"Int J Infect Dis"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.cell.2019.10.029","article-title":"Differences in tumor microenvironment dictate T helper lineage polarization and response to immune checkpoint therapy","volume":"179","author":"Jiao","year":"2019","journal-title":"Cell"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20082173","article-title":"Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1","volume":"206","author":"Kuang","year":"2009","journal-title":"J Exp Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.03179-15","article-title":"Prime, shock, and kill: Priming CD4 T cells from HIV patients with a BCL-2 antagonist before HIV reactivation reduces HIV reservoir size","volume":"90","author":"Cummins","year":"2016","journal-title":"J Virol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00037-18","article-title":"HIV Protease-generated Casp8p41, when bound and inactivated by Bcl2, is degraded by the proteasome","volume":"92","author":"Natesampillai","year":"2018","journal-title":"J Virol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00012-17","article-title":"Maintenance of the HIV reservoir is antagonized by selective BCL2 inhibition","volume":"91","author":"Cummins","year":"2017","journal-title":"J Virol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1172\/JCI132374","article-title":"BCL-2 antagonism sensitizes cytotoxic T cell-resistant HIV reservoirs to elimination ex vivo","volume":"130","author":"Ren","year":"2020","journal-title":"J Clin Invest"},{"key":"B28","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1083\/jcb.201708092","article-title":"Senescence and aging: Causes, consequences, and therapeutic avenues","volume":"217","author":"McHugh","year":"2018","journal-title":"J Cell Biol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2020.00178","article-title":"Aging, cellular senescence, and progressive multiple sclerosis","volume":"14","author":"Papadopoulos","year":"2020","journal-title":"Front Cell Neurosci"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2013.05.039","article-title":"The hallmarks of aging","volume":"153","author":"Lopez-Otin","year":"2013","journal-title":"Cell"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/s0006-291x(03)00402-9","article-title":"Bcl-2 promotes premature senescence induced by oncogenic ras","volume":"303","author":"Tombor","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2020.593630","article-title":"Senescent cell depletion through targeting BCL-family proteins and mitochondria","volume":"11","author":"Fan","year":"2020","journal-title":"Front Physiol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2021.107943","article-title":"The interplay between apoptosis and cellular senescence: Bcl-2 family proteins as targets for cancer therapy","volume":"230","author":"Basu","year":"2022","journal-title":"Pharmacol Ther"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2007.07.003","article-title":"Cellular senescence in cancer and aging","volume":"130","author":"Collado","year":"2007","journal-title":"Cell"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2006.10.003","article-title":"The regulation of INK4\/ARF in cancer and aging","volume":"127","author":"Kim","year":"2006","journal-title":"Cell"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2772","article-title":"Senescence in tumours: evidence from mice and humans","volume":"10","author":"Collado","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00020.2018","article-title":"Cellular senescence: Aging, cancer, and injury","volume":"99","author":"Calcinotto","year":"2019","journal-title":"Physiol Rev"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.27316","article-title":"Cellular senescence and tumor suppressor gene p16","volume":"130","author":"Rayess","year":"2012","journal-title":"Int J Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.578599","article-title":"Mitochondria targeted viral replication and survival strategies-prospective on SARS-CoV-2","volume":"11","author":"Gatti","year":"2020","journal-title":"Front Pharmacol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9040982","article-title":"Master regulator analysis of the SARS-CoV-2\/Human interactome","volume":"9","author":"Guzzi","year":"2020","journal-title":"J Clin Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/71316","article-title":"Human homologue of s. pombe Rad9 interacts with BCL-2\/BCL-xL and promotes apoptosis","volume":"2","author":"Komatsu","year":"2000","journal-title":"Nat Cell Biol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s00705-005-0632-8","article-title":"Bcl-2 inhibits the caspase-dependent apoptosis induced by SARS-CoV without affecting virus replication kinetics","volume":"151","author":"Bordi","year":"2006","journal-title":"Arch Virol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1089\/dna.2005.24.496","article-title":"Apoptosis induced by the SARS-associated coronavirus in vero cells is replication-dependent and involves caspase","volume":"24","author":"Ren","year":"2005","journal-title":"DNA Cell Biol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20050698","article-title":"Bcl-xL inhibits T-cell apoptosis induced by expression of SARS coronavirus e protein in the absence of growth factors","volume":"392","author":"Yang","year":"2005","journal-title":"Biochem J"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20131461","article-title":"The SARS-coronavirus membrane protein induces apoptosis via interfering with PDK1-PKB\/Akt signalling","volume":"464","author":"Tsoi","year":"2014","journal-title":"Biochem J"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00090-07","article-title":"Induction of apoptosis by the severe acute respiratory syndrome coronavirus 7a protein is dependent on its interaction with the bcl-XL protein","volume":"81","author":"Tan","year":"2007","journal-title":"J Virol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.anndiagpath.2020.151565","article-title":"Cytologic and molecular correlates of SARS-CoV-2 infection of the nasopharynx","volume":"48","author":"Nuovo","year":"2020","journal-title":"Ann Diagn Pathol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3390\/cells9091962","article-title":"Targeting the sAC-dependent cAMP pool to prevent SARS-Cov-2 infection","volume":"9","author":"Aslam","year":"2020","journal-title":"Cells"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2020.611275","article-title":"Modulation of autophagy by SARS-CoV-2: A potential threat for cardiovascular system","volume":"11","author":"Randhawa","year":"2020","journal-title":"Front Physiol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0237300","article-title":"Structural insight into the role of novel SARS-CoV-2 e protein: A potential target for vaccine development and other therapeutic strategies","volume":"15","author":"Sarkar","year":"2020","journal-title":"PloS One"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abf8609","article-title":"Age-dependent regulation of SARS-CoV-2 cell entry genes and cell death programs correlates with COVID-19 severity","volume":"7","author":"Inde","year":"2021","journal-title":"Sci Adv"},{"key":"B52","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus remdesivir for hospitalized adults with covid-19","volume":"384","author":"Kalil","year":"2021","journal-title":"N Engl J Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2003.11.001","article-title":"Viral bcl-2 homologs and their role in virus replication and associated diseases","volume":"1644","author":"Polster","year":"2004","journal-title":"Biochim Biophys Acta"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(04)01103-X","article-title":"Pathogenesis of filoviral haemorrhagic fevers","volume":"4","author":"Mahanty","year":"2004","journal-title":"Lancet Infect Dis"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/nature01326","article-title":"The immunopathogenesis of sepsis","volume":"420","author":"Cohen","year":"2002","journal-title":"Nature"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/s0090-8258(03)00439-6","article-title":"Co-Overexpression of p53 and bcl-2 proteins in HPV-induced squamous cell carcinoma of the uterine cervix","volume":"91","author":"Grace","year":"2003","journal-title":"Gynecol Oncol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1803936115","article-title":"Revisiting the role of IRF3 in inflammation and immunity by conditional and specifically targeted gene ablation in mice","volume":"115","author":"Yanai","year":"2018","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-7-59","article-title":"A poxvirus bcl-2-like gene family involved in regulation of host immune response: sequence similarity and evolutionary history","volume":"7","author":"Gonzalez","year":"2010","journal-title":"Virol J"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2006.08.001","article-title":"Role of bcl-2 expression for productive herpes simplex virus 2 replication","volume":"356","author":"Sciortino","year":"2006","journal-title":"Virology"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28062","article-title":"The presence of merkel cell polyomavirus is associated with deregulated expression of BRAF and bcl-2 genes in non-small cell lung cancer","volume":"133","author":"Lasithiotaki","year":"2013","journal-title":"Int J Cancer"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-012-1310-3","article-title":"Bcl-2 expression indicates better prognosis of merkel cell carcinoma regardless of the presence of merkel cell polyomavirus","volume":"461","author":"Sahi","year":"2012","journal-title":"Virchows Arch"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/s0042-6822(03)00491-4","article-title":"High level of bcl-2 counteracts apoptosis mediated by a live rabies virus vaccine strain and induces long-term infection","volume":"314","author":"Thoulouze","year":"2003","journal-title":"Virology"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.70.1.663-666.1996","article-title":"Bcl-2 alters influenza virus yield, spread, and hemagglutinin glycosylation","volume":"70","author":"Olsen","year":"1996","journal-title":"J Virol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.26.15_suppl.7008","article-title":"Effect of the addition of oblimersen (Bcl-2 antisense) to fludarabine\/cyclophosphamide for relapsed\/refractory chronic lymphocytic leukemia (CLL) on survival in patients who achieve CR\/nPR: Five-year follow-up from a randomized phase III study","volume":"26","author":"Rai","year":"2008","journal-title":"J Clin Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210220","article-title":"The bcl-2 apoptotic switch in cancer development and therapy","volume":"26","author":"Adams","year":"2007","journal-title":"Oncogene"},{"key":"B66","article-title":"Oblimersen for the treatment of patients with chronic lymphocytic leukemia","volume":"3","author":"Cheson","year":"2007","journal-title":"Ther Clin Risk Manage"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/1212369","article-title":"Drugs and clinical approaches targeting the antiapoptotic protein: A review","volume":"2019","author":"Han","year":"2019","journal-title":"BioMed Res Int"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1464","article-title":"Lessons learnt from genasense's failure","volume":"3","author":"Frantz","year":"2004","journal-title":"Nat Rev Drug Discovery"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210028","article-title":"A novel bcl-2\/Bcl-X(L)\/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma","volume":"26","author":"Chauhan","year":"2007","journal-title":"Oncogene"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2006.08.027","article-title":"The BH3 mimetic ABT-737 targets selective bcl-2 proteins and efficiently induces apoptosis via Bak\/Bax if mcl-1 is neutralized","volume":"10","author":"van Delft","year":"2006","journal-title":"Cancer Cell"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2010.05.061","article-title":"Mcl-1; the molecular regulation of protein function","volume":"584","author":"Thomas","year":"2010","journal-title":"FEBS Lett"},{"key":"B72","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.chom.2017.12.004","article-title":"Getting the \"Kill\" into \"Shock and kill\": Strategies to eliminate latent HIV","volume":"23","author":"Kim","year":"2018","journal-title":"Cell Host Microbe"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.144","article-title":"ABT-737, a small molecule bcl-2\/Bcl-xL antagonist, increases antimitotic-mediated apoptosis in human prostate cancer cells","volume":"1","author":"Parrondo","year":"2013","journal-title":"PeerJ"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1301721","article-title":"Aging and cytomegalovirus infection differentially and jointly affect distinct circulating T cell subsets in humans","volume":"192","author":"Wertheimer","year":"2014","journal-title":"J Immunol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70261-8","article-title":"Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity","volume":"11","author":"Wilson","year":"2010","journal-title":"Lancet Oncol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-015-2883-8","article-title":"Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors","volume":"76","author":"Tolcher","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"B77","unstructured":"AgencyEM\n          EMA\/523594\/2018: European medicines agency decision P\/0255\/2018 2018"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1126\/science.abe4832","article-title":"Senolytics reduce coronavirus-related mortality in old mice","volume":"373","author":"Camell","year":"2021","journal-title":"Science"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13141","article-title":"Senolytic drugs: from discovery to translation","volume":"288","author":"Kirkland","year":"2020","journal-title":"J Intern Med"},{"key":"B80","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2147\/CE.S42568","article-title":"An evidence-based review of obatoclax mesylate in the treatment of hematological malignancies","volume":"8","author":"Goard","year":"2013","journal-title":"Core Evid"},{"key":"B81","unstructured":"FDA Approves new drug for chronic lymphocytic leukemia in patients with a specific chromosomal abnormality2016"},{"key":"B82","volume-title":"FDA Grants regular approval to venetoclax in combination for untreated acute myeloid leukemia","year":"2020"},{"key":"B83","unstructured":"FDA Approves venetoclax for CLL and SLL2019"},{"key":"B84","year":"2016"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.213157","article-title":"Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvement","volume":"104","author":"Reda","year":"2019","journal-title":"Haematologica"},{"key":"B86","volume-title":"Fact sheet for healthcare providers emergency use authorization (EUA) of baricitinib","year":"2020"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.121718","article-title":"Single-cell RNA sequencing reveals microglia-like cells in cerebrospinal fluid during virologically suppressed HIV","volume":"3","author":"Farhadian","year":"2018","journal-title":"JCI Insight"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1172\/JCI127413","article-title":"Persistent HIV-infected cells in cerebrospinal fluid are associated with poorer neurocognitive performance","volume":"129","author":"Spudich","year":"2019","journal-title":"J Clin Invest"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001109","article-title":"Inflammation, immune activation, and cardiovascular disease in HIV","volume":"30","author":"Nou","year":"2016","journal-title":"Aids"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.768695","article-title":"Targeting macrophage dysregulation for viral infections: Novel targets for immunomodulators","volume":"12","author":"Reece","year":"2021","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1033672\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T10:31:34Z","timestamp":1670581894000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1033672\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,9]]},"references-count":90,"alternative-id":["10.3389\/fimmu.2022.1033672"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1033672","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,9]]},"article-number":"1033672"}}